BACKGROUND Randomized trials have not demonstrated significant differences in stroke, heart failure, or mortality
failed to demonstrate that rhythm control improved cardiovascular outcomes or mortality relative to rate control (7) . Further, rhythm control was associated with higher hospitalizations (4-6).
However, post hoc nonrandomized analysis of the AFFIRM trial suggested that patients who successfully maintained sinus rhythm had lower mortality than those who failed to maintain sinus rhythm (8) .
It is unclear if adverse effects of antiarrhythmic drug therapy mitigated benefits of maintaining sinus rhythm, or if sinus rhythm was just a correlate of other confounding predictors of survival not captured in the analysis.
Contemporary observational data on hospitalized patients with AF suggest that rhythm control may have a marginal mortality benefit over rate control during long-term follow-up (9) . Overall, in the U.S.
clinical practice, one-third of AF patients are on a rhythm control strategy (10) . Both international and U.S. data suggest that there are significant differences in the population of patients selected for rhythm control versus rate control (10) (11) (12) (13) . Results from the aforementioned trials have presumably impacted clinical practice and approach towards use of antiarrhythmic drugs, and we sought to evaluate the contemporary clinical practice of rhythm control versus rate control. We utilized data from the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry to evaluate comparative outcomes for rhythm control versus rate control in a broad practice-based cohort of patients with AF.
METHODS
The ORBIT-AF registry is a registry of U.S. patients with AF who are treated by internists, cardiologists or electrophysiologists. The ORBIT-AF registry enrolled patients from a nationally representative sample of 176 U.S. practices between June 29, 2010 and August 9, 2011. The rationale and design of the registry have been previously described (14) . In brief, patients were eligible if they were $18 years of age with electrocardiographic (ECG) evidence of AF and were able to provide informed consent and follow-up. Exclusion criteria included <6 months of life expectancy or AF due to a reversible cause such as pulmonary embo- Noheria et al.
Rhythm Versus Rate Control for AF A P R I L 2 0 1 6 : 2 2 1 -9 STUDY OUTCOMES. We assessed the following outcomes at follow-up: 1) all-cause death; 2) cardiovas- was adjusted for the propensity to receive either treatment by inverse propensity weighting. The propensity score predicting AF management strategy was derived using logistic regressions using imputed data.
The propensity score was adjusted for all independent predictors of AF management strategy identified in our prior publication describing the clinical practice of rhythm versus rate control (10) and all additional independent predictors using backward selection, as associated with any of the outcomes of interest for this paper (p < 0.05 required to stay in model). Continuous covariates in the propensity model were checked for linearity (no nonlinear relationships were detected). All subjects with a propensity below the 1 percentile were excluded from the adjusted models. The hazard ratio (HR) of rhythm control subjects relative to rate control subjects is reported for all models, along with the corresponding 95% confidence interval (CI) and p value. 
Rhythm Versus Rate Control for AF 
Rhythm Versus Rate Control for AF Table 2 ). 
As shown in
Noheria et al. Table 4 ).
All of our results remained qualitatively similar
when we excluded all rate control patients with a prior history of antiarrhythmic drug therapy. Similarly, there was no appreciable change in the results with inclusion of baseline oral anticoagulation status as an additional covariate for the propensity scores used in the adjusted models.
DISCUSSION
In this analysis of AF management in contemporary clinical practice, we did not find an independent difference in mortality, heart failure, or systemic embolic events with rhythm or rate control strategies.
However, we did observe a higher rate of cardiovas- patients on rate control (11) . The therapeutic target of Although rhythm control was not statistically superior to rate control strategy in our registry, we observed trends towards improvements in all outcomes except cardiovascular hospitalizations. In particular, there was a trend toward reduction in overall mortality as well as reduction in composite of death, stroke, non-CNS embolism, and TIA. Although we cannot exclude the influence of chance or unmeasured confounding, these trends may suggest a role for rhythm control strategy in specific subgroups of patients that need to be identified. We did not observe a difference in the new diagnosis of heart failure between the rhythm control and rate control groups. This finding, however, does not preclude a role for rhythm control in patients presenting with congestive heart failure presumed secondary to previously undiagnosed AF.
ANTIARRHYTHMIC DRUGS AND CONGESTIVE HEART FAILURE. We did not observe any increase in newonset congestive heart failure with rhythm control strategy. In the RECORDAF registry the rate of hospitalizations for heart failure was lower with rhythm control strategy, presumably on account of better controlled heart rates (11) . Regardless, antiarrhythmic drugs should be used in patients with structural heart disease with caution due to risk of ventricular proarrhythmia. In the AF-CHF trial of AF patients with left ventricular ejection fraction #35%, there was no evidence of increased mortality with rhythm control (6) . Notably, 82% of patients received amiodarone as the antiarrhythmic drug, and literature supports no increased mortality with amiodarone in AF patients (16) . 
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